Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Vertebral compression fracture augmentation; IR, pain, spine surgeons. Main billing specialties: interventional radiology and pain management.
Medicare fee-for-service kyphoplasty & vertebroplasty cases in the 42 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (184 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 71 | 5,916−5%/yr | −5%/yr | 2.61.9× | 52% | 6,240 in 2030+0.9%/yr |
| Texas | 43 | 3,866−5.3%/yr | −5.3%/yr | 1.81.3× | 26% | 3,550 in 2030−1.4%/yr |
| California | 23 | 2,826−4.2%/yr | −4.2%/yr | 0.80.6× | 27% | 3,540 in 2030+3.8%/yr |
| Virginia | 21 | 1,869−3.9%/yr | −3.9%/yr | 1.81.3× | 28% | 2,170 in 2030+2.6%/yr |
| Illinois | 22 | 1,781−6.9%/yr | −6.9%/yr | 1.30.9× | 16% | 1,860 in 2030+0.7%/yr |
| Ohio | 15 | 1,537−7.3%/yr | −7.3%/yr | 1.41.0× | 1% | 1,360 in 2030−2.1%/yr |
| New York | 12 | 1,432−3.1%/yr | −3.1%/yr | 0.80.6× | 29% | 1,740 in 2030+3.3%/yr |
| Pennsylvania | 13 | 1,396−2.9%/yr | −2.9%/yr | 1.00.8× | 12% | 1,330 in 2030−0.7%/yr |
| North Carolina | 16 | 1,376−9.2%/yr | −9.2%/yr | 1.41.0× | 27% | 1,380 in 20300%/yr |
| Georgia | 9 | 1,369−5.8%/yr | −5.8%/yr | 1.61.2× | 22% | 1,270 in 2030−1.2%/yr |
| Oklahoma | 16 | 1,356−6.7%/yr | −6.7%/yr | 2.82.1× | 48% | 1,260 in 2030−1.2%/yr |
| Missouri | 13 | 1,235−7.5%/yr | −7.5%/yr | 2.01.5× | 5% | 1,060 in 2030−2.5%/yr |
| Michigan | 11 | 1,216−8.7%/yr | −8.7%/yr | 1.41.1× | 12% | 1,000 in 2030−3.2%/yr |
| Indiana | 13 | 1,180−9.3%/yr | −9.3%/yr | 1.61.2× | 19% | 1,300 in 2030+1.7%/yr |
| Massachusetts | 16 | 1,156−2.5%/yr | −2.5%/yr | 1.20.9× | 7% | 1,260 in 2030+1.5%/yr |
| Arizona | 15 | 1,110+2.9%/yr | +2.9%/yr | 1.51.1× | 90% | 1,600 in 2030+6.3%/yr |
| Tennessee | 12 | 1,040−6.3%/yr | −6.3%/yr | 1.51.1× | 60% | 1,070 in 2030+0.5%/yr |
| Kansas | 15 | 1,030−5.7%/yr | −5.7%/yr | 2.51.9× | 11% | 920 in 2030−1.8%/yr |
| Maryland | 8 | 809+0.7%/yr | +0.7%/yr | 0.90.7× | 57% | 730 in 2030−1.6%/yr |
| Alabama | 5 | 752−5.3%/yr | −5.3%/yr | 1.71.3× | 33% | 680 in 2030−1.7%/yr |
| South Carolina | 7 | 691−9%/yr | −9%/yr | 1.00.7× | 12% | 870 in 2030+3.9%/yr |
| Washington | 8 | 686−4.6%/yr | −4.6%/yr | 0.90.7× | 43% | 570 in 2030−2.9%/yr |
| Arkansas | 11 | 674−8.7%/yr | −8.7%/yr | 1.81.3× | 37% | 540 in 2030−3.7%/yr |
| New Jersey | 6 | 624−5.3%/yr | −5.3%/yr | 0.60.4× | 59% | 630 in 2030+0.1%/yr |
| Louisiana | 3 | 600−4.7%/yr | −4.7%/yr | 1.41.1× | 24% | 620 in 2030+0.4%/yr |
| Mississippi | 7 | 578−8.4%/yr | −8.4%/yr | 1.51.1× | 34% | 660 in 2030+2.3%/yr |
| Wisconsin | 5 | 577−4.4%/yr | −4.4%/yr | 1.00.7× | 12% | 650 in 2030+2%/yr |
| Kentucky | 5 | 575−12%/yr | −12%/yr | 1.20.9× | 21% | 690 in 2030+3%/yr |
| Colorado | 0 | 538−5.5%/yr | −5.5%/yr | 1.10.8× | 18% | 560 in 2030+0.6%/yr |
| Utah | 8 | 520−2.1%/yr | −2.1%/yr | 2.31.7× | 89% | 620 in 2030+3%/yr |
| Nebraska | 6 | 473−8.9%/yr | −8.9%/yr | 1.81.3× | 16% | 510 in 2030+1.3%/yr |
| Minnesota | 1 | 310−5.8%/yr | −5.8%/yr | 0.70.5× | 8% | 290 in 2030−1.1%/yr |
| Idaho | 3 | 261−4.7%/yr | −4.7%/yr | 1.30.9× | 0% | 490 in 2030+11%/yr |
| Iowa | 2 | 213−11%/yr | −11%/yr | 0.50.4× | 0% | 130 in 2030−7.9%/yr |
| New Hampshire | 2 | 210−1.5%/yr | −1.5%/yr | 0.90.7× | 9% | 240 in 2030+2%/yr |
| Connecticut | 2 | 191−16%/yr | −16%/yr | 0.60.4× | 39% | 210 in 2030+1.2%/yr |
| North Dakota | 4 | 184+3.2%/yr | +3.2%/yr | 1.81.4× | 0% | 210 in 2030+2.6%/yr |
| Oregon | 0 | 181−0.7%/yr | −0.7%/yr | 0.40.3× | 100% | 310 in 2030+9.2%/yr |
| Nevada | 0 | 169−17%/yr | −17%/yr | 0.60.4× | 32% | 230 in 2030+5.1%/yr |
| Delaware | 2 | 124−1.1%/yr | −1.1%/yr | 0.70.5× | 32% | 260 in 2030+13%/yr |
| New Mexico | 1 | 106−5.5%/yr | −5.5%/yr | 0.50.3× | 0% | 90 in 2030−3.6%/yr |
| South Dakota | 1 | 100−11%/yr | −11%/yr | 0.80.6× | 0% | 110 in 2030+1.7%/yr |
Professional codes (what the surgeon bills): CPT 22513, 22514, 22510, 22511.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 26 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 19 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Stryker | 3 |
| Xelite Biomed | 3 |
| Gs Medical | 2 |
| Hyprevention | 2 |
| Medtronic | 2 |
| Amber Implants | 1 |
| Biopsybell | 1 |
| Bonwrx | 1 |
| Dragon Crown Medical | 1 |
| G-21 | 1 |
| Globus Medical | 1 |
| Hanchang | 1 |
Product codes: NDN (cement, bone, vertebroplasty), OBL (cement, bone, pre-formed, modular, polymeric, vertebroplasty), OBM (cement, bone, vertebroplasty, pre-formed, modular). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +9 pts since 2019, to 32%.
The 10 busiest do 35% of the cases CMS names in Florida; 37 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Decompression & minimally invasive spine | 2,544 | 105,318−5.9%/yr | −5.9%/yr | 112,600 in 2030+1.1%/yr |
| Lumbar fusion | 2,352 | 95,082−1.5%/yr | −1.5%/yr | 107,700 in 2030+2.1%/yr |
| Cervical fusion & disc arthroplasty | 962 | 47,639−4%/yr | −4%/yr | 52,600 in 2030+1.7%/yr |
| SI joint fusion | 147 | 7,710+13%/yr | +13%/yr | 14,700 in 2030+11%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 6 companies reported engagement with surgeons in the covered states worth $1.2M in consulting, speaking, meals and travel tied to these products, about $2,722 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.